Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics

Abstract:
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT® nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics

Research Triangle Park, NC | Posted on January 7th, 2009

"Delivery has been the most significant hurdle to realizing the broad potential of siRNA therapeutics. We are very pleased to form a partnership with Abbott, which we hope will enable significant progress in addressing this problem," said Neal Fowler, Chief Executive Officer of Liquidia. "By combining Abbott's research and development capabilities with Liquidia's particle design and delivery expertise, we hope to enable the use of siRNA for therapy and provide more targeted, effective treatment options for cancer patients."

Under the terms of the agreement, Liquidia will provide Abbott with certain rights to PRINT technology for the development and commercialization of siRNA therapeutics. Financial terms were not disclosed.

About siRNA Therapeutics - Short interfering RNA (siRNA) are small, double stranded RNA molecules that selectively silence and regulate the activity of human genes through the process of RNA interference (RNAi). Since many diseases are caused by the inappropriate expression of certain genes, the ability to selectively silence disease-associated genes represents a novel and powerful method for treating disease. The primary challenge to achieving broad application of siRNA therapeutics is effective delivery of the molecules to target tissues and cell types.

####

About Liquidia Technologies, Inc.
Liquidia Technologies Inc. is a privately-held nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a variety of life and materials science applications. Within life sciences, Liquidia is focused on developing novel vaccines and Engineered Drug Therapies™ for nucleic acid delivery and inhaled therapeutics. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone and colleagues at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina.

For more information, please click here

Contacts:
Liquidia Technologies
Elle Pishny
919-328-4361

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Diamonds closer to becoming ideal semiconductors: Researchers find new method for doping single crystals of diamond May 25th, 2016

Light can 'heal' defects in new solar cell materials: Defects in some new electronic materials can be removed by making ions move under illumination May 24th, 2016

Attosecond physics: A switch for light-wave electronics May 24th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Nanomedicine

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Nanoscale Trojan horses treat inflammation May 24th, 2016

Programmable materials find strength in molecular repetition May 23rd, 2016

Tiny packages may pack powerful treatment for brain tumors: Nanocarrier provides efficient delivery of chemotherapeutic drug May 23rd, 2016

Announcements

Diamonds closer to becoming ideal semiconductors: Researchers find new method for doping single crystals of diamond May 25th, 2016

Light can 'heal' defects in new solar cell materials: Defects in some new electronic materials can be removed by making ions move under illumination May 24th, 2016

Attosecond physics: A switch for light-wave electronics May 24th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Patents/IP/Tech Transfer/Licensing

Programmable materials find strength in molecular repetition May 23rd, 2016

Syracuse University chemists add color to chemical reactions: Chemists in the College of Arts and Sciences have come up with an innovative new way to visualize and monitor chemical reactions in real time May 19th, 2016

Researchers integrate diamond/boron nitride crystalline layers for high-power devices May 12th, 2016

New tool allows scientists to visualize 'nanoscale' processes May 4th, 2016

Alliances/Trade associations/Partnerships/Distributorships

The CEA Announces Expanded Collaboration with Intel to Advance Cutting-edge Research and Innovation in Key Digital Areas May 17th, 2016

Solliance realizes first up-scaled Perovskite based PV modules with 10% efficiency: Holst Centre, imec and ECN pave the road to upscaling Perovskite PV modules May 10th, 2016

Industrial Nanotech, Inc. Expands Distribution Network in US and Internationally May 9th, 2016

Albertan Science Lab Opens in India May 7th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic